(NASDAQ: ZVSA) Zyversa Therapeutics's forecast annual revenue growth rate of N/A is not forecast to beat the US Biotechnology industry's average forecast revenue growth rate of N/A, and while it is not forecast to beat the US market's average forecast revenue growth rate of N/A.
Zyversa Therapeutics's revenue in 2024 is $0.On average, 1 Wall Street analysts forecast ZVSA's revenue for 2028 to be $26,582,010, with the lowest ZVSA revenue forecast at $26,582,010, and the highest ZVSA revenue forecast at $26,582,010.
In 2029, ZVSA is forecast to generate $69,565,120 in revenue, with the lowest revenue forecast at $2,422,760 and the highest revenue forecast at $136,707,480.